Quarter of total pain sales will be attributable to novel drug classes by 2028

The overall pain market will maintain $38 billion in sales in 2028 across the major pharmaceutical markets (USA, France, Germany, Italy, Spain, the UK and Japan), new research indicates.

The loss of sales due to the generic entry of several blockbuster pain therapies in the first half of the 2013-2028 forecast period will be offset by the uptake of emerging agents in current drug classes as well as products representing novel drug classes, according to a new report from Decision Resources Group, which expects anti-nerve growth factor (anti-NGF) monoclonal antibodies to be the most commercially successful novel analgesic drug class, garnering $7.7 billion in sales by the end of 2028.

Other key findings from the Pharmacor report, titled Novel Approaches to Pain Therapy, include: